AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05419609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACE-Q | Aesthetics - Satisfaction With Lower Face and Jawline
Description: Completed by patients. The FACE-Q \| Aesthetics - Satisfaction With Lower Face and Jawline is a 5-item questionnaire. Each item is rated 1-4, with 1 being Very Dissatisfied and 4 being Very Satisfied. Lower scores suggest the person may be less pleased with the appearance of their lower face and jawline.
Study NCT05419609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FACE-Q | Aesthetics - Recovery Early Symptoms
Description: Completed by patients. The FACE-Q \| Aesthetics - Recovery Early Symptoms is a 17-item questionnaire. Each item is rated 1-4, with 1 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms early in their recovery following an aesthetic facial procedure.
Study NCT05419609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACE-Q | Aesthetics - Recovery Early Symptoms
Description: Completed by patients. The FACE-Q \| Aesthetics - Recovery Early Symptoms is a 17-item questionnaire. Each item is rated 1-4, with 1 being Not at all and 4 being Extremely. Lower scores suggest the person may be experiencing fewer symptoms early in their recovery following an aesthetic facial procedure.
Study NCT05419609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FACE-Q | Aesthetics - Satisfaction with Outcome
Description: Completed by patients. The FACE-Q \| Aesthetics - Satisfaction with Outcome is a 6-item questionnaire. Each item is rated 1-4, with 1 being Definitely disagree and 4 being Definitely agree. Lower scores suggest the person may be less pleased with their final appearance following surgery and the decision to have an aesthetic facial procedure.
Study NCT05419609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACE-Q | Aesthetics - Satisfaction with Outcome
Description: Completed by patients. The FACE-Q \| Aesthetics - Satisfaction with Outcome is a 6-item questionnaire. Each item is rated 1-4, with 1 being Definitely disagree and 4 being Definitely agree. Lower scores suggest the person may be less pleased with their final appearance following surgery and the decision to have an aesthetic facial procedure.
Study NCT05419609 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: FACE-Q | Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck
Description: Completed by patients. The FACE-Q \| Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck is a 15-item questionnaire. Each item is rated 1-3, with 1 being Not at all and 3 being A lot. Lower scores suggest the person may be experiencing fewer chronic symptoms following an aesthetic facial procedure.
Study NCT05419609 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: FACE-Q | Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck
Description: Completed by patients. The FACE-Q \| Aesthetics - Adverse Effects: Cheeks, Lower Face, Neck is a 15-item questionnaire. Each item is rated 1-3, with 1 being Not at all and 3 being A lot. Lower scores suggest the person may be experiencing fewer chronic symptoms following an aesthetic facial procedure.
Study NCT04987385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Protein supplementation
Description: Patients will receive a box with 7 sealable of 90-gram protein containers that will be dissolved in maximal 1L liquid (i.e., water or milk) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake. A wash-out period of minimum 7 days between Protein supplementation and Oral urea will be performed.
Study NCT04987385 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: Oral urea
Description: Patients will receive a box with 7 30-grams urea sealable containers. The total daily oral urea dosage of 30 grams that will be dissolved in maximal 1L of a liquid of choice (water, milk, juice, ...) that should be integrated in the usual daily hydration volume documented at baseline and taken daily for the following 7 days, while keeping their usual meal composition and usual fluid intake.
Study NCT05734430 — intervention group
Intervention type: GENETIC
Intervention: Genetic profiling
Description: Whole exome sequencing
Study NCT05734430 — intervention group
Intervention type: OTHER
Intervention: Retrospective tissue procurement
Description: Collection of archived fixed-formalin, paraffin-embedded (FFPE) primary appendix tumor tissues that were previously removed
Study NCT05886829 — intervention group
Intervention type: COMBINATION_PRODUCT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray
Study NCT06122376 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: U-shaped Power Toothbrush
Description: Twice daily brushing for 30 seconds with fluoride toothpaste
Study NCT06122376 — intervention group
Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Soft Manual Toothbrush
Description: Twice daily brushing for two minutes with fluoride toothpaste
Study NCT05618951 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lower Trapezius Strengthening Exercises
Description: Lower Trapezius strengthening exercise includes:~1. Latissimus pull down~2. Prone V- raise~3. Modified Prone Cobra
Study NCT05209152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AMG 176
Description: Administered as an intravenous (IV) infusion.
Study NCT05209152 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Azacitidine
Description: Administered as an IV infusion or subcutaneous (SC) injection.
Study NCT03823001 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: virtual biopsy (VB) monitoring protocol
Description: 1. PSA bi-annually or more often according to the discretion of the urologist.~2. Annual DRE.~3. Visit with the urologist bi-annually.~4. Multi-parametric MRI (mpMRI) every year for 3 years.~5. Transrectal ultrasound (TRUS) biopsy at the end of the 3rd year.
Study NCT05596565 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Supervised Exercise by a physiotherapist via face to face
Description: Participants in group-1 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via face to face.~Participants in group-2 will be included in an exercise program for 6 weeks, 2 days a week and 45 minutes each session with supervised by a physiotherapist via video conference
Study NCT04641078 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Darolutamide
Description: 600 mg BID
Study NCT04641078 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: metastasis-directed treatment
Description: stereotactic body radiotherapy
Study NCT05479136 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PET imaging with 18F fluciclovine
Description: PET with 18F fluciclovine injection, 185 MBq (5 mCi) ± 20%, delivered as an intravenous bolus
Study NCT04641078 — intervention group
Intervention type: RADIATION
Group type: OTHER
Intervention: metastasis-directed treatment
Description: stereotactic body radiotherapy
Study NCT05629897 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Sessions of cognitive stimulation
Description: 40 sessions of cognitive stimulation of approximately 20 minutes duration per session are carried out, using the COPERIA platform.
Study NCT05139745 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: BTL-899
Description: BTL-899 treatment
Study NCT05139745 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL-899
Description: BTL-899 treatment
Study NCT05824611 — intervention group
Intervention type: OTHER
Intervention: collect movement data from epileptic seizures
Description: non-invasive recording of movement data during care as usual
Study NCT04734015 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Together Overcoming Diabetes (TOD)
Description: Curriculum approaches health through a holistic lens of spiritual, mental, physical and emotional wellness. American Indian Family Health Coaches conduct motivational interviewing to help participant dyads (adult caregivers with Type 2 diabetes and their youth) set attainable goals and work through obstacles to reach those goals.
Study NCT05962762 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Human Umbilical Cord Mesenchymal Stem Cells
Description: The trial was conducted sequentially from the low dose group to the high dose group, with 3-6 subjects enrolled in each dose group. The trial was conducted on a case-by-case basis in the high dose group, with each subject in the high dose group being enrolled in subsequent subjects only after completion of at least 7 days of post-dose safety observation. Each subject received only one corresponding dose. All subjects received experimental drugs and conventional treatment during the study period.~All subjects in each test dose group will complete a 4-week (28-day) dose-limiting toxicity (DLT) After the observational evaluation period, a decision will be made by the investigator and sponsor based on a discussion of relevant safety data whether to start the next dose group.
Study NCT05670535 — intervention group
Intervention type: OTHER
Intervention: Visual analogue scale (VAS) for dyspareunia
Description: Dyspareunia scores between 0 to 10 points
Study NCT05670535 — intervention group
Intervention type: OTHER
Intervention: Visual analogue scale (VAS) for vaginal dryness
Description: Vaginal dryness scores between 0 to 10 points
Study NCT05670535 — intervention group
Intervention type: OTHER
Intervention: The European League Against Rheumatism Sjögren's Syndrome Disease Activity Index (ESSDAI)
Description: Sjögren's Syndrome Disease Activity Index scores between 0 to 3 points
Study NCT05670535 — intervention group
Intervention type: OTHER
Intervention: The European League Against Rheumatism Sjögren's Syndrome Patient Reported Index (ESSPRI)
Description: Sjögren's Syndrome Patient Reported Index scores between 0 to 10 points
Study NCT04749238 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: NucleoCapture device
Description: Device: 100 ml NucleoCapture selective DNA adsorber. Treatment with NucleoCapture in one arm
Study NCT04326205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial direct current stimulation, tDCS
Description: The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
Study NCT04326205 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial direct current stimulation, tDCS
Description: The participants will receive a-tDCS over the ipsilesional M1, without any active arm practice for 20 minutes.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without tDCS followed by 30 minutes of functional task practice.
Study NCT04326205 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: functional electrical stimulation, FES
Description: The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice.
Study NCT04326205 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: functional electrical stimulation, FES
Description: The participants will start the FES-assisted MT. During this period, participants will perform simple wrist or finger extension with their unaffected UE while the affected wrist or fingers will receive FES within the mirror-box.~Hence, movement extension will be achieved in the affected side while the participant will view the reflection of the normal movement patterns of their unaffected UE. Then the electrodes will be removed, and the participants will receive an additional 20 minutes of MT without FES followed by 30 minutes of functional task practice.
Study NCT04326205 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: no stimulation
Description: Both tDCS and FES will not be used in this section.
Study NCT05160857 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Herombopag Olamine
Description: The initial dose of hetropapa is recommended to be 7.5mg, once a day, oral on an empty stomach, and can only be eaten after oral administration for 2 hours, so as to avoid taking it with meals.
Study NCT05871424 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: buprenorphine patch group
Description: 5 mcg/h buprenorphine patch will be applied preoperatively
Study NCT05871424 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: placebo group
Description: simple dressing tape only will be applied
Study NCT04996277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: angiography
Description: All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
Study NCT04996277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Thrombus suction
Description: All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
Study NCT04996277 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Fibrinolytic therapy
Description: All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
Study NCT04996277 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Medication stabilized the condition
Description: All STEMI patients will be treated according to the hospital's standard procedures and the plaque will be monitored for 7-30 days to stabilize. Treatment options for STEMI include: March thrombus aspiration without balloon or stent implantation; Stabilization with drug therapy in a relatively small hospital that does not provide PCI, and transfer to a tertiary hospital for further evaluation; Thrombolytic therapy.
Study NCT05097794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015-1
Description: - Administration to the BR1015-1 group: 60 mg of BR1015-1 will be administered one tablet once a day, five-day repeated doses.
Study NCT05097794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015-2
Description: - Administration to the BR1015-2 group: 1.5 mg of BR1015-2 will be administered one tablet once a day, five-day repeated doses.
Study NCT05097794 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BR1015-1 + BR1015-2
Description: - Co-administration to the BR1015-1+BR1015-2 group: 60 mg of BR1015-1 one tablet and 1.5 mg of BR1015-2 one tablet will be co-administered once a day, five-day repeated doses.
Study NCT04784533 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CTP-543
Description: Oral dosing
Study NCT04784533 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Oral dosing
Study NCT05773807 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Bispectral index
Description: In the BIS group, the anesthesiologist set the target controlled infusion (TCI) parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes to maintain the BIS value at 45-60.
Study NCT05773807 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Observer's assessment alert Sedation
Description: In the OAA/S group, the anesthesiologist set the TCI parameters according to the patient's height, weight, gender and age. The initial plasma target concentration was set to 1.5ug/ml, and the target concentration would be increased or decreased 0.5ug/ ml every two minutes maintain the OAA/S value at 1 point.
Study NCT05773807 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Gastroscopy
Description: Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
Study NCT05773807 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Gastroscopy
Description: Gastroscopy would be performed when the BIS value was 45-60 or the OAA/S score was 1
Study NCT05773807 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Propofol
Description: Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
Study NCT05773807 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Propofol
Description: Propofol infusion was administered under the guidance of the BIS or OAA/S before the gastroscopy, and the infusion was stopped at the end of gastroscopy
Study NCT06348251 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: FoodSteps
Description: Participants will get access to the FoodSteps digital intervention with coaching for 16 weeks and receive a weekly stipend benefit to aid with implementing health behavior changes
Study NCT04806061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sodium bicarbonate
Description: sodium bicarbonate 8.4% to achieve urinary pH >7.5
Study NCT04806061 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: standard care
Description: standard care
Study NCT05410925 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Recombinant staphylokinase
Description: Intravenous injection of r-SAK is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study NCT05410925 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Intravenous injection of placebo is administered within 10 minutes after diagnosis of acute ST-segment elevation myocardial infarction
Study NCT06458062 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Pocket Colposcope
Description: Each patient will receive treatment in order to prevent cervical cancer
Study NCT06262048 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tamsulosin Hydrochloride
Description: 2 days pre-op, day of surgery, 2 days post-op
Study NCT06262048 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 2 days pre-op, day of surgery, 2 days post-op
Study NCT05740527 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: Noninvasive electrical stimulation of genital nerves
Description: A closed-loop system (in-bladder sensor, radio, algorithm, and stimulator) is being tested for the feasibility of inhibiting neurogenic bladder overactivity in an ambulatory setting.
Study NCT06339450 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: walk tours
Description: * During 5 days the patient will walk 4 hours in urban green space (open-space areas reserved for parks and other green spaces, including plant life, water features -also referred to as blue spaces and other kinds of natural environment). The 3 hours walk tour includes a lunch break of one hour in the green space.~* During 5 days the patient will walk 4 hours in urban space (including 3 hours walk around the city and one-hour lunch break.
Study NCT05345405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Dyadic CARE
Description: Dyadic CARE involves two telehealth sessions with a clinician, the survivor, and a supporter of the survivor's choice. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
Study NCT05345405 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Supporter-Only CARE
Description: Supporter-only CARE involves two telehealth sessions with a clinician and a supporter of the survivor's choice, without the survivor present. Session content uses cognitive-behavioral strategies (e.g., encouraging non-avoidance) to encourage communication and improve supporters' responses in trauma-related conversations. Between sessions, both the survivor and the supporter are instructed to review session content and have guided discussions with the assistance of a workbook.
Study NCT05818540 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Eclipse novel CPAP mask
Description: Participants will wear the mask for 6 hours a night for 60 days.
Study NCT05818540 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: ResMed P-10 mask
Description: Participants will wear the mask for 6 hours a night for 60 days.